ArticleRespirology (Carlton, Vic.)2026
Rapid Serological Detection of Anti-GM-CSF Autoantibodies in Autoimmune Pulmonary Alveolar Proteinosis Using a Novel Immunochromatographic Test.
Article in Respirology (Carlton, Vic.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The burden of autoimmune pulmonary alveolar proteinosis: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Rapid Serological Detection of Anti-GM-CSF Autoantibodies in Autoimmune Pulmonary Alveolar Proteinosis Using a Novel Immunochromatographic Test.Respirology (Carlton, Vic.) · 2026Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
objectivesAnti-GM-CSF autoantibodies (GMAbs) are essential biomarkers for diagnosing autoimmune pulmonary alveolar proteinosis (APAP). While enzyme-linked immunosorbent assay (ELISA) is commonly used, it is time-consuming and requires specialised equipment. We developed a novel immunochromatographic test (ICT) for rapid detection of GMAbs in clinical settings.
methodsICT was designed using a gold colloid aggregation method. The test line intensity was calibrated to be close to the ELISA cutoff of 1.65 U/mL using polyclonal anti-GM-CSF antibodies purified from the pooled patient sera. Validation was performed in 211 APAP and 171 non-APAP cases. The sensitivity, specificity, and correlation with ELISA were assessed.
resultsUsing known concentrations of serum from APAP patients, the grey zone concentration, which was difficult to judge by visual inspection, was found to be below 3.5 U/mL. In serological diagnosis of 211 cases with APAP and 171 cases with non-APAP lung diseases, the sensitivity and specificity by five examiners were 100% and 98.8%, respectively. When the GMAbs positive serum was serially diluted, the end point dilution titre showed a strong correlation overall (ρ = 0.93) with the antibody concentration determined by the conventional ELISA method, but the correlation was weaker in the low concentration range below 60 U/mL (ρ = 0.67), suggesting that the accuracy of ICT was reduced in the lower concentration range.
conclusionThis ICT offers a practical alternative to ELISA for APAP serological diagnosis. It enables rapid testing in clinical settings and supports the implementation of GM-CSF inhalation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.